{
    "nct_id": "NCT06096779",
    "official_title": "A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis",
    "inclusion_criteria": "* Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic patients\n* Disease that is not amenable to curative surgical and/or locoregional therapies\n* No prior systemic treatment (including systemic investigational agents) for locally advanced or metastatic and/or unresectable HCC\n* Measurable disease (at least one untreated target lesion) according to RECIST v1.1\n* ECOG Performance Status of 0-2 within 7 days prior to initiation of study treatment\n* Child-Pugh B7 or B8 cirrhosis at screening and within 7 days prior to study treatment\n* Adequate hematologic and end-organ function\n* Life expectancy of at least 12 weeks\n* Female participants of childbearing potential must be willing to avoid pregnancy and egg donation\n\nGeneral\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnancy or breastfeeding\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies\n* Treatment with investigational therapy within 28 days prior to initiation of study treatment\n* Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure\n* Treatment with systemic immunostimulatory agents\n* Treatment with systemic immunosuppressive medication\n* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment\n* Inadequately controlled hypertension\n* Active or history of autoimmune disease or immune deficiency\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan\n* Patients who have a known concurrent malignancy that is progressing or requires active treatment, who have not completely recovered from treatment, or who have a significant malignancy history that, in the opinion of the investigator, should preclude participation.\n* Known fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Prior allogeneic stem cell or solid organ transplantation\n* Listed for liver transplantation\n* Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)\n* Untreated or incompletely treated esophageal and/or gastric varices with bleeding or that are at high risk for bleeding\n* A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment\n* Grade â‰¥3 hemorrhage or bleeding event within 6 months prior to initiation of study treatment\n* History of hepatic encephalopathy requiring hospitalization or treatment escalation within 6 months prior to study treatment, or any continued symptoms of encephalopathy despite medical management\n* History, planned, or recommended placement of transjugular intrahepatic portosystemic shunt (TIPS)\n* History of ascites requiring therapeutic paracentesis over the last 3 months\n* History of spontaneous bacterial peritonitis within last 12 months",
    "miscellaneous_criteria": "General"
}